National Bank of Canada
PCRX icon

National Bank of Canada’s Pacira BioSciences PCRX Stock Holding History

National Bank of Canada’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30,200
Closed -$966K – 2874
2023
Q4 		$966K Buy
+30,200
New +$884K ﹤0.01% 1160

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

National Bank of Canada's PCRX Position: Q1 2024 in Review

National Bank of Canada sold out of Pacira BioSciences (PCRX) in Q1 2024, closing a stake of 30,200 shares — an estimated $966K sold.

National Bank of Canada first reported a position in PCRX in Q4 2023 and held it in 1 quarter. The position peaked at $966K in Q4 2023. 271 funds tracked by Wall St. Rank hold PCRX as of Q1 2024.

  • National Bank of Canada reported no remaining Pacira BioSciences position as of Q1 2024 after selling out during the quarter.
  • National Bank of Canada sold 30,200 Pacira BioSciences shares in Q1 2024, an estimated $966K.
  • National Bank of Canada first reported a position in Pacira BioSciences in Q4 2023 and held it in 1 quarter.
  • National Bank of Canada's Pacira BioSciences position peaked at $966K in Q4 2023.
  • 271 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2024.

Based on National Bank of Canada's 13F filing for Q1 2024, filed 13 May 2024.